Novel set of genes linked with epithelial ovarian cancer patient survival

NewsGuard 100/100 Score

Researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the United States and the United Kingdom have used two genome-wide association studies (GWAS) - one from the U.S. and one from the U.K. - to detect a novel set of genes found to be associated with epithelial ovarian cancer patient survival. The discovery could open the door to new therapies for treating epithelial ovarian cancer (EOC), the most lethal kind of gynecologic malignancy.

The study appeared in a recent issue of Cancer Epidemiology, Biomarkers & Prevention published by the American Association for Cancer Research.

The research team applied gene set analysis (GSA) for the first time to epithelial ovarian cancer gene databases. The gene set analysis mapped 857genes related to EOC that pass signals "downstream" to components in the cell which, in turn, are activated and trigger a change in the state of the cell.

One of the most significant gene sets they analyzed was comprised of a set of eight genes involved in macrolide (a class of drugs) "binding" which interact with immune suppressant FK506 and involve intracellular signaling.

Other studies have indicated that the binding protein (FKBP65) was "highly expressed in ovarian epithelium." FKBP65 has also been found to be inversely associated with the expression of tumor suppressor gene P53.

Researchers expect that the results of their GSA can be used to focus on the role and function of these specific gene sets and may ultimately help uncover additional genetic causes of complex traits.

"Epithelial ovarian cancer is the fifth leading cause of cancer mortality among women in the U.S.," said study co-author Thomas A. Sellers, Ph.D., M.P.H., Moffitt executive vice president and director of the Moffitt Research Institute. "Because women may vary in their ability to eradicate disease or tolerate treatment, genetic association studies like ours are needed to identify the genetic bases related to outcome. Until this study, GWAS have not uncovered any outcome-associated genetic traits for EOC."

The gene set analysis the researchers used in this study focused specifically on EOC survival data in the genome-wide association studies. According to Sellers, GSA helps to systematically narrow the search for relevant genes.

"Unfortunately, GSA does not allow us to determine the gene set's effect on outcome," explained Sellers. "GSA does, however, contribute to our understanding of the relationship between EOC genetic variation and mortality. Our results using GSA may lead to the discovery of other possible gene sets and novel genes related to EOC that can be followed up in future studies."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiny DNA circles are key drivers of cancer formation, study suggests